These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 32977343)

  • 1. New Horizons: Emerging Therapies and Targets in Thyroid Cancer.
    Ringel MD
    J Clin Endocrinol Metab; 2021 Jan; 106(1):e382-e388. PubMed ID: 32977343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer.
    Fullmer T; Cabanillas ME; Zafereo M
    Front Endocrinol (Lausanne); 2021; 12():720723. PubMed ID: 34335481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Therapies for Advanced Thyroid Cancer.
    Laha D; Nilubol N; Boufraqech M
    Front Endocrinol (Lausanne); 2020; 11():82. PubMed ID: 32528402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trials as valid therapeutic options for patients with cancer.
    Adashek JJ; LoRusso PM; Hong DS; Kurzrock R
    Nat Rev Clin Oncol; 2019 Dec; 16(12):773-778. PubMed ID: 31477881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.
    Moreno L; Barone G; DuBois SG; Molenaar J; Fischer M; Schulte J; Eggert A; Schleiermacher G; Speleman F; Chesler L; Geoerger B; Hogarty MD; Irwin MS; Bird N; Blanchard GB; Buckland S; Caron H; Davis S; De Wilde B; Deubzer HE; Dolman E; Eilers M; George RE; George S; Jaroslav Š; Maris JM; Marshall L; Merchant M; Mortimer P; Owens C; Philpott A; Poon E; Shay JW; Tonelli R; Valteau-Couanet D; Vassal G; Park JR; Pearson ADJ
    Eur J Cancer; 2020 Sep; 136():52-68. PubMed ID: 32653773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.
    Zhu Z; Liu W; Gotlieb V
    Crit Rev Oncol Hematol; 2016 Mar; 99():91-9. PubMed ID: 26708040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma.
    Wisdom AJ; Mowery YM; Riedel RF; Kirsch DG
    Cancer; 2018 Oct; 124(19):3819-3829. PubMed ID: 29723407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [TGF-β-targeted immunotherapy aiming for new and efficient treatments of cancer].
    Foughali R; Marie JC
    Med Sci (Paris); 2020 Jan; 36(1):77-79. PubMed ID: 32014103
    [No Abstract]   [Full Text] [Related]  

  • 9. [New treatments in immuno-oncology: a revolution and a formidable scientific and clinical challenge].
    Champiat S; Soria JC
    Med Sci (Paris); 2017; 33(6-7):563-564. PubMed ID: 28990546
    [No Abstract]   [Full Text] [Related]  

  • 10. [Targeted therapy in thyroid cancer: Towards a treatment card].
    Lkhoyaali S; Benhmida S; Ait Elhaj M; Layachi M; Bensouda Y; Errihani H
    Pathol Biol (Paris); 2015 Feb; 63(1):1-6. PubMed ID: 25555494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy.
    Turner N; Hamidi S; Ouni R; Rico R; Henderson YC; Puche M; Alekseev S; Colunga-Minutti JG; Zafereo ME; Lai SY; Kim ST; Cabanillas ME; Nurieva R
    Front Immunol; 2024; 15():1369780. PubMed ID: 38868771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy for thyroid cancer: An updated review of investigational agents.
    Deshpande HA; Gettinger SN; Sosa JA
    Curr Opin Investig Drugs; 2010 Jun; 11(6):661-8. PubMed ID: 20496261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigational therapies for metastatic thyroid carcinoma.
    Tuttle RM; Leboeuf R
    J Natl Compr Canc Netw; 2007 Jul; 5(6):641-6. PubMed ID: 17623615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advanced thyroid cancers: new era of treatment.
    Mohammed AA; El-Shentenawy A
    Med Oncol; 2014 Jul; 31(7):49. PubMed ID: 24908065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF inhibitor therapy for melanoma, thyroid and colorectal cancers: development of resistance and future prospects.
    Rahman MA; Salajegheh A; Smith RA; Lam AK
    Curr Cancer Drug Targets; 2014; 14(2):128-43. PubMed ID: 24446739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Not Available].
    Schlumberger M
    Bull Acad Natl Med; 2015 Nov; 199(8-9):1395-1407. PubMed ID: 29874427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging therapeutics in refractory renal cell carcinoma.
    Koshkin VS; Rini BI
    Expert Opin Pharmacother; 2016 Jun; 17(9):1225-32. PubMed ID: 27112171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical therapy for advanced forms of thyroid cancer.
    Rajhbeharrysingh U; Taylor M; Milas M
    Surg Clin North Am; 2014 Jun; 94(3):541-71. PubMed ID: 24857576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Advances in Oncology.
    Liu J; Pandya P; Afshar S
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging therapeutic agents for advanced non-small cell lung cancer.
    Chen R; Manochakian R; James L; Azzouqa AG; Shi H; Zhang Y; Zhao Y; Zhou K; Lou Y
    J Hematol Oncol; 2020 May; 13(1):58. PubMed ID: 32448366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.